Kristin Abate

KPTI

CHIEF ACCOUNTING OFFICER · KARYOPHARM THERAPEUTICS INC. · CIK 0002045943

FILING MIX · LIFETIME40%/60%

BUYS

SELLS

TOTAL VALUE

$14.7K

COMPANIES

ACTIVE SINCE

Feb 2025

HOLDINGS NOW

23,801

AVG SELL PX

$6.91

Trades · vs SPY

Loading price series…

Performance · forward returns vs SPY

8 backtested trades · 8 horizons · 18 pendingHow are these numbers computed? →

Forward-return performance of every backtestable P/S trade by Kristin Abate, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.

HORIZON	TRADES	WIN RATE	INSIDER RETURN	SPY RETURN	MEAN EXCESS	MEDIAN EXCESS	T-STAT
7d	8	+62.50%	-1.48%	-0.09%	-1.38%	-6.57%	—
14d	8	+75.00%	-3.78%	-0.43%	-3.35%	-2.06%	—
30d	8	+62.50%	+5.45%	-0.54%	+5.98%	-7.12%	—
60d	8	+62.50%	-0.36%	+0.65%	-1.01%	-10.05%	—
90d	8	+37.50%	+11.98%	+3.79%	+10.64%	+14.94%	—
180d	8(3 pending)	+20.00%	+24.00%	+4.70%	+19.30%	+25.19%	—
1y	8(7 pending)	+0.00%	+43.64%	+19.13%	+24.52%	+24.52%	—
2y	8(8 pending)	—	—	—	—	—	—

How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.

Holdings over time

KPTI · 23,801 shares · as of May 14, 2026

Trading cadence · quarterly flow

BUY ● SELL ●

2025

2026

FLOW · 6 buys / 9 sellsCOVERAGE · 6 quarters

Form 4 filings · all activity

COMPANY	TYPE	SHARES	PRICE	VALUE	HELD AFTER	TRADE DATE	FILED	DETAILS
KPTI KARYOPHARM THERAPEUTICS INC.	SALE Chief Accounting Officer	53	$9.50	$504	23,801	May 14, 2026	May 15, 2026 ↗	View →
KPTI KARYOPHARM THERAPEUTICS INC.	PURCHASEGRANT Stock grant	121	—	—	23,854	May 13, 2026	May 15, 2026 ↗	View →
KPTI KARYOPHARM THERAPEUTICS INC.	SALE Chief Accounting Officer	559	$9.41	$5.3K	22,063	Mar 2, 2026	Mar 3, 2026 ↗	View →
KPTI KARYOPHARM THERAPEUTICS INC.	SALE Chief Accounting Officer	50	$7.03	$352	22,622	Jan 28, 2026	Jan 29, 2026 ↗	View →
KPTI KARYOPHARM THERAPEUTICS INC.	PURCHASEGRANT Stock grant	92	—	—	22,672	Jan 27, 2026	Jan 29, 2026 ↗	View →
KPTI KARYOPHARM THERAPEUTICS INC.	SALE Chief Accounting Officer	265	$5.96	$1.6K	22,580	Jan 21, 2026	Jan 22, 2026 ↗	View →
KPTI KARYOPHARM THERAPEUTICS INC.	PURCHASEGRANT Stock grant	12,799	—	—	22,845	Oct 15, 2025	Oct 16, 2025 ↗	View →
KPTI KARYOPHARM THERAPEUTICS INC.	SALE Chief Accounting Officer	362	$6.30	$2.3K	10,046	Oct 1, 2025	Oct 3, 2025 ↗	View →
KPTI KARYOPHARM THERAPEUTICS INC.	SALE Chief Accounting Officer	23	$6.43	$148	10,408	Sep 15, 2025	Sep 16, 2025 ↗	View →
KPTI KARYOPHARM THERAPEUTICS INC.	PURCHASEGRANT Stock grant	46	—	—	10,431	Sep 12, 2025	Sep 16, 2025 ↗	View →
KPTI KARYOPHARM THERAPEUTICS INC.	SALE Chief Accounting Officer	12	$6.78	$81	9,463	Sep 3, 2025	Sep 4, 2025 ↗	View →
KPTI KARYOPHARM THERAPEUTICS INC.	SALE Chief Accounting Officer	238	$4.00	$952	9,475	Jul 22, 2025	Jul 23, 2025 ↗	View →
KPTI KARYOPHARM THERAPEUTICS INC.	SALE Chief Accounting Officer	571	$6.29	$3.6K	9,713	Mar 4, 2025	Mar 6, 2025 ↗	View →
KPTI KARYOPHARM THERAPEUTICS INC.	PURCHASEGRANT Stock grant	933	—	—	10,284	Feb 28, 2025	Mar 4, 2025 ↗	View →
KPTI KARYOPHARM THERAPEUTICS INC.	PURCHASEGRANT Stock grant	1,866	—	—	1,866	Feb 28, 2025	Mar 4, 2025 ↗	View →

Other insiders · KPTI

Loading peer insiders…

About this filer

CIK 0002045943

ROLE

Chief Accounting Officer

PRIMARY

KPTI

COMPANIES

ACTIVE SINCE

Feb 2025

MARKETPEEL · /INSIDER/0002045943DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE

Kristin Abate

The morning brief, before the bell.